ProBiotix Health #PBX – Q3 2024 Trading Update

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a Q3 2024 trading update (for the nine months to 30 September 2024) which shows ongoing strong momentum in the business.  Key highlights:  ·      Sales +39% to £1.525m (2023: £1.099m)   ·      Gross Profit +40% to £874k (2023: £623k) ·      Gross Profit margin stable at […]